Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 to 75

Evaluating Tasimelteon for Delayed Sleep-Wake Phase Disorder

Official title: A Double-Blind, Randomized, Two-Period Crossover Study to Evaluate the Effects of Tasimelteon Vs. Placebo in Subjects with Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant

Run by Vanda Pharmaceuticals · NCT06701396 · Data updated 2026-11-12

This study is testing if a new sleep medication called tasimelteon can help people with Delayed Sleep-Wake Phase Disorder who have a specific genetic variant improve their sleep patterns.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment60 (estimated)
SponsorVanda Pharmaceuticals
Industry-sponsored
Locations1 site (Çankaya, Ankara)
StatusRecruiting
StartedOctober 8, 2024
Main results expectedJune 30, 2025
Study endsJune 30, 2025
Registry record updatedNovember 22, 2024
Trial IDNCT06701396 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are men and women aged 18 to 75 with a confirmed diagnosis of DSWPD and who are carriers of the CRY1Δ11 variant.

Probably not a fit

Patients who have had major surgery, trauma, or illness in the past 30 days, or who are pregnant or breastfeeding, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a double-blind, randomized, two-period crossover study designed to assess the efficacy and safety of a single oral dose of tasimelteon compared to a placebo in individuals diagnosed with Delayed Sleep-Wake Phase Disorder (DSWPD) who also carry the CRY1Δ11 genetic variant. Participants will be monitored for improvements in their sleep patterns and overall circadian rhythm. The study aims to gather data on how tasimelteon affects sleep-wake cycles in this specific patient population.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients suffering from DSWPD, potentially improving their quality of life.

How similar studies have gone: Other studies have explored treatments for sleep disorders, but the specific approach of using tasimelteon in this genetic context is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Ability and acceptance to provide written informed consent.
* A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).
* Carrier of CRY1Δ11 variant.
* Men or women between 18 - 75 years, inclusive.
* Body Mass Index (BMI) of ≥ 18 and ≤ 40 kg/m\^2.

Exclusion Criteria:

* Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.
* Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.
* A positive test for substances of abuse.
* Current tobacco user.

Where it's running

  • Vanda Investigational Site
    Çankaya, Ankara, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.